| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
202 |
| Employees |
146 |
| Revenues (TTM) (Millions $) |
26 |
| Net Income (TTM) (Millions $) |
-65 |
| Cash Flow (TTM) (Millions $) |
-26 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Spectrum Pharmaceuticals Inc. is a biopharmaceutical company that focuses on the development and commercialization of oncology and hematology drug products. The company is headquartered in Irvine, California, and was founded in 198 Spectrum Pharmaceuticals operates in the United States and markets its products internationally.
Spectrum Pharmaceuticals has a diverse pipeline of products in various stages of development. The company's product portfolio includes products for the treatment of hematologic and solid tumor cancers, including non-Hodgkin's lymphoma, leukemia, multiple myeloma, and breast, colon, and lung cancers. The company's lead product is a combination of chemotherapy drugs called Zevalin, which is used to treat non-Hodgkines lymphoma.
The company licensed its first product, Apaziquone, a novel drug for the treatment of bladder cancer, to Allergan in 2015 and obtained a significant upfront payment along with milestone and royalty payments. Spectrum Pharmaceuticals also has a licensing agreement with Taiho Pharmaceutical for the development and commercialization of the oncology drug candidate Fusilev in the United States.
Other products in Spectrum Pharmaceuticalse portfolio include ROLONTIS, which is approved by the US Food and Drug Administration (FDA) for the treatment of neutropenia in patients undergoing chemotherapy, and POZIOTINIB, a drug candidate for the treatment of non-small cell lung cancer. The company is also developing other oncology drugs candidates in the pre-clinical and clinical stage of development.
Spectrum Pharmaceuticals' financial performance over the past few years has been mixed. The company reported a net loss in 2019 and 2020, although its total revenue did increase in 2020. The company has a market capitalization of approximately $350 million as of 202
Overall, Spectrum Pharmaceuticals Inc. is a biopharmaceutical company with a diverse portfolio of products in various stages of development for the treatment of oncology and hematology conditions. The company's strategic partnership with other biopharmaceutical companies and its focus on developing novel therapeutic products positions it well for continued growth in the industry.
Company Address: Pilot House - Lewis Wharf, 2 Atlantic Ave Boston 2110 MA
Company Phone Number: 586-3900 Stock Exchange / Ticker: NASDAQ SPPI
|
%
